306,781 Shares in Harmony Biosciences Holdings, Inc. $HRMY Purchased by Tieton Capital Management LLC

Tieton Capital Management LLC acquired a new stake in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) during the 2nd quarter, HoldingsChannel.com reports. The fund acquired 306,781 shares of the company’s stock, valued at approximately $11,170,000. Harmony Biosciences accounts for about 3.2% of Tieton Capital Management LLC’s holdings, making the stock its 16th biggest position.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the company. BlackRock Inc. bought a new position in Harmony Biosciences in the 2nd quarter worth about $258,583,000. Dimensional Fund Advisors LP boosted its position in shares of Harmony Biosciences by 13.4% during the first quarter. Dimensional Fund Advisors LP now owns 2,076,510 shares of the company’s stock worth $58,157,000 after buying an additional 245,784 shares during the period. SG Americas Securities LLC grew its holdings in Harmony Biosciences by 109.9% in the 1st quarter. SG Americas Securities LLC now owns 2,018,174 shares of the company’s stock worth $56,529,000 after buying an additional 1,056,507 shares in the last quarter. State Street Corp grew its holdings in Harmony Biosciences by 0.5% in the 4th quarter. State Street Corp now owns 1,661,850 shares of the company’s stock worth $62,186,000 after buying an additional 8,246 shares in the last quarter. Finally, LSV Asset Management increased its position in Harmony Biosciences by 3.9% in the 4th quarter. LSV Asset Management now owns 1,657,093 shares of the company’s stock valued at $62,008,000 after acquiring an additional 62,200 shares during the period. 86.23% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

HRMY has been the topic of several recent analyst reports. HC Wainwright reaffirmed a “buy” rating and set a $55.00 target price on shares of Harmony Biosciences in a research note on Thursday, July 16th. Weiss Ratings raised Harmony Biosciences from a “hold (c)” rating to a “hold (c+)” rating in a report on Monday. Needham & Company LLC lifted their price objective on shares of Harmony Biosciences from $45.00 to $50.00 and gave the company a “buy” rating in a research note on Tuesday, August 4th. Mizuho increased their target price on shares of Harmony Biosciences from $50.00 to $51.00 and gave the company an “outperform” rating in a research report on Friday, July 31st. Finally, Zacks Research cut shares of Harmony Biosciences from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, August 11th. Four research analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Harmony Biosciences presently has an average rating of “Hold” and an average price target of $45.50.

Harmony Biosciences Stock Up 2.8%

HRMY opened at $39.93 on Thursday. Harmony Biosciences Holdings, Inc. has a one year low of $25.52 and a one year high of $40.87. The company has a debt-to-equity ratio of 0.13, a quick ratio of 3.45 and a current ratio of 3.48. The stock’s fifty day moving average is $36.19 and its 200-day moving average is $32.71. The company has a market capitalization of $2.33 billion, a PE ratio of 12.96, a P/E/G ratio of 0.36 and a beta of 0.96.

Harmony Biosciences (NASDAQ:HRMY) last announced its earnings results on Tuesday, August 4th. The company reported $1.28 earnings per share for the quarter, beating the consensus estimate of $0.96 by $0.32. The business had revenue of $261.28 million during the quarter, compared to analysts’ expectations of $250.77 million. Harmony Biosciences had a return on equity of 20.06% and a net margin of 18.88%.The company’s quarterly revenue was up 30.3% on a year-over-year basis. During the same quarter last year, the business posted $0.92 earnings per share. On average, equities analysts predict that Harmony Biosciences Holdings, Inc. will post 3.77 EPS for the current fiscal year.

About Harmony Biosciences

Harmony Biosciences Holdings, Inc is a commercial‐stage biopharmaceutical company focused on developing and delivering therapies for people with rare neurological and endocrine diseases. Founded in 2017 and headquartered in Plymouth Meeting, Pennsylvania, Harmony Biosciences went public in 2020 and trades on the Nasdaq under the ticker HRMY. The company’s mission centers on identifying and advancing medicines that address critical unmet needs in patient populations underserved by existing treatments.

The company’s flagship product is WAKIX (pitolisant), the first and only histamine H3 receptor antagonist/inverse agonist approved by the U.S.